Loading company…
Oviva Therapeutics develops treatments focused on women's health and ovarian function.
Oviva is developing a drug targeting folliculogenesis, the process through which ovarian follicles mature and ovulate. It is a majority-owned pipeline company of Cambrian Biopharma. Founded in 2021 and based in New York, it raised USD 11.5 million in seed funding from Cambrian Biopharma in May 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in